Editorial Volume 7, Issue 6 pp 350—351

Figure 1. Implications of HCC intratumor heterogeneity for tumor classification and targeted therapy. A biopsy taken from tumor area 2 does not necessarily represent the whole tumor. This may result in a short falling tumor classification as type B, and potentially in an incomplete therapy response due to sensitivity of only one tumor subclone (mutation B, biomarker B‘, pink).